- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Tactile Systems Technology Inc(TCMD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TCMD
11/13/2026: TCMD (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Tactile Systems Technology Inc is a specialized medical device company focused on providing home-based therapies for lymphedema and chronic respiratory conditions. Its business model is built upon a direct-to-patient sales approach and robust clinical evidence supporting the efficacy of products like the Flexitouch system. The primary investment opportunity lies in the company's potential to capture a large, underserved patient market, further bolstered by the acquisition of the AffloVest product line. However, the company faces significant risks from reimbursement policy volatility, intense competition, and the necessity of successful operational execution. It is best suited for growth-oriented investors who can tolerate sector-specific regulatory and valuation risks while monitoring clinical adoption trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company targets large, underserved markets with high potential for recurring therapy utilization. |
| Momentum investor | Mixed fit | Momentum is often tied to reimbursement updates and sales execution, requiring positive signals. |
| Value investor | Mixed fit | Valuation is sensitive to growth projections rather than established earnings multiples. |
| Dividend investor | Weak fit | The company does not pay dividends as it retains capital for business expansion. |
| Low-risk investor | Weak fit | Exposure to healthcare reimbursement policy creates inherent volatility for investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is susceptible to changes in healthcare sentiment and company-specific growth news. |
| Valuation risk | Medium | Growth expectations are priced into the stock, leaving it sensitive to earnings surprises. |
| Competition risk (Medical devices) | Medium | Established players and potential new entrants could impact market share or pricing power. |
| Business quality | Medium | The model relies on specific clinical efficacy and patient compliance. |
| Dividend income | Low / none | Investors should not expect income generation from this asset. |
| Execution risk | Medium | Successful scaling requires effective sales force expansion and continued physician education. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 600.58M USD | Price to earnings Ratio 26.03 | 1Y Target Price 36.33 |
Price to earnings Ratio 26.03 | 1Y Target Price 36.33 | ||
Volume (30-day avg) 228.1K shares | Beta 0.89 | 52 Weeks Range 20.53 - 37.77 | Updated Date 11/14/2026 |
52 Weeks Range 20.53 - 37.77 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.03 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 62.5%
- Active BUY / eligible
- 5 / 8
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 227.07% | Avg. Invested days 57 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Lymphedema Therapy | Sales and rental of Flexitouch and Entre systems. | The primary revenue engine driven by patients seeking home-based relief for swelling. |
| Airway Clearance | Sales of the AffloVest portable system. | A secondary revenue stream expanding the company's reach into respiratory care. |
| Geography | Primarily the United States. | The business is currently concentrated in the US market, making reimbursement policy the key macro driver. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-11-02 | When After Market | Estimate 0.3 | Actual 0.31 |
Profitability
Profit Margin 6.68% | Operating Margin (TTM) 9.44% |
Management Effectiveness
Return on Assets (TTM) 7.64% | Return on Equity (TTM) 11.02% |
Valuation
Trailing PE 26.03 | Forward PE 19.12 | Enterprise Value 542.76M | Price to Sales(TTM) 1.69 |
Enterprise Value 542.76M | Price to Sales(TTM) 1.69 | ||
Enterprise Value to Revenue 1.52 | Enterprise Value to EBITDA 12.64 | Shares Outstanding 22.40M | Shares Floating 20.34M |
Shares Outstanding 22.40M | Shares Floating 20.34M | ||
Percent Insiders 3.22 | Percent Institutions 107.16 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

